STOCK TITAN

Medpace (MEDP) CEO August Troendle sells 11,824 shares around $600

(Very High)
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Common Stock totaling 11,824 shares over two days in August 2026. He sold 11,366 shares on August 12, 2026 at a weighted average price of $601.53 per share and 458 shares on August 13, 2026 at a weighted average price of $600.39 per share, both effected pursuant to a limit order during an open window period. The filing also reports 4,733,019 shares of Common Stock held indirectly through Medpace Investors, LLC, for which Troendle is the sole manager with voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Troendle August J.
Role President & CEO
Sold 11,824 shs ($7.11M)
Type Security Shares Price Value
Sale Common Stock F1, F3 458 $600.39 $275K
Sale Common Stock F1, F2 11,366 $601.53 $6.84M
holding Common Stock F4 -- -- --
Holdings After Transaction: Common Stock — 603,978 shares (Direct); Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)
Footnotes (4)
  1. F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
  2. F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
  3. F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.345 to $600.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
  4. F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Shares sold 2026-08-12 11,366 shares at $601.53 per share Open-market sale of Common Stock on August 12, 2026
Shares sold 2026-08-13 458 shares at $600.39 per share Open-market sale of Common Stock on August 13, 2026
Total shares sold 11,824 shares Aggregate of reported Common Stock sales in August 2026
Indirectly held shares 4,733,019 shares Common Stock held indirectly via Medpace Investors, LLC as of August 12, 2026
Sale price range 2026-08-12 $600.00 to $603.64 Multiple transactions underlying weighted average price of $601.53
Sale price range 2026-08-13 $600.345 to $600.47 Multiple transactions underlying weighted average price of $600.39
limit order market
"transactions were effected pursuant to a limit order placed by the Reporting Person"
A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.
weighted average price financial
"The reported price is a weighted average price. These shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirectly beneficially own financial
"may be deemed to indirectly beneficially own the securities of the Issuer held by MPI"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein"

FAQ

What insider transactions did MEDP CEO August J. Troendle report in this Form 4?

August J. Troendle reported two open-market sales of Medpace Holdings Common Stock totaling 11,824 shares on August 12–13, 2026. The trades were executed pursuant to a limit order during an open trading window.

At what prices did the MEDP CEO sell his shares in this filing?

The CEO’s reported sales used weighted average prices: $601.53 per share for 11,366 shares on August 12, 2026, and $600.39 per share for 458 shares on August 13, 2026, both from multiple transaction prices within stated ranges.

How many Medpace (MEDP) shares did the CEO sell in total?

Across the reported transactions, the CEO sold 11,824 shares of Medpace Common Stock. This consists of 11,366 shares sold on August 12, 2026 and 458 shares sold on August 13, 2026 in open-market transactions.

What indirect Medpace (MEDP) holdings are reported for the CEO?

The filing lists 4,733,019 shares of Medpace Common Stock held indirectly through Medpace Investors, LLC. August J. Troendle manages this entity and has voting and investment control, while disclaiming beneficial ownership beyond his pecuniary interest.

Were the MEDP CEO’s sales under a limit order or trading plan?

The footnotes state the transactions were effected pursuant to a limit order placed during an open window period. The Form 4 does not describe these trades as being executed under a Rule 10b5-1 trading plan.

How are the MEDP CEO’s reported sale prices described?

Each sale’s reported price is a weighted average price. The August 12 trades ranged from $600.00 to $603.64, and the August 13 trades ranged from $600.345 to $600.47, with full details available upon request to the issuer or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Troendle August J.

(Last)(First)(Middle)
C/O MEDPACE HOLDINGS, INC.
5375 MEDPACE WAY

(Street)
CINCINNATI OHIO 45227

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/12/2026S(1)11,366D$601.53(2)604,436D
Common Stock08/13/2026S(1)458D$600.39(3)603,978D
Common Stock4,733,019IBy Medpace Investors, LLC(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.345 to $600.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/Stephen P. Ewald, Attorney-in-Fact for August J. Troendle08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)